External therapy with topical steroids has been used for a long time. To date, topical glucocorticosteroids (TGCSs) head the list of all topical drugs. TGCSs play a role of powerful pathogenetic tool and can quickly lower or reduce the inflammatory lesions of the skin and eliminate the subjective symptoms of dermatoses (itching, burning), which significantly facilitates vocational rehabilitation, activities of daily living, have positive impact on the psychoemotional state, and significantly improves the quality of life of patients. Currently, the repertoire of TGCSs registered in Russian Federation includes more than 40 names. Such an abundance of drugs with similar mechanism of action poses certain difficulties when choosing a particular drug for a particular patient with steroid-responsive dermatosis. Development of an up-to-date algorithm of age-appropriate (for children and adults) topical therapy of steroid-responsive dermatoses, depending on the severity of the main clinical manifestations of the disease, is a question of present interest. Objective. The objective is to develop the modern algorithm of the topical therapy of steroid-responsive dermatoses with allowance for the severity, nature, localization of pathological process, duration of the disease, previous treatment and its effectiveness, and patient’s age and to conduct practical testing of the algorithm. Material and Methods. The work was done at the Ural Research Institute of Dermatology and Immunopathology of the Russian Ministry of Health. Results. Our long-term experience in management of patients with steroid- responsive dermatoses shows that the choice between TGCSs and non-steroidal drugs, for example, calcineurin antagonists, in each case largely depends on patient’s condition during the first visit to the dermatologist. We have proposed an up-to-date algorithm for selecting topical preparation in the topical treatment of steroid-responsive dermatoses with allowance for the severity, nature, localization of the pathological process, duration of disease, previous treatment and its effectiveness, and patient’s age. When including drugs in the algorithm, we gave preference to modern TGCSs with high safety profile and proven efficacy. Conclusion. The differentiated approach to the choice of topical therapy of patients with steroid-responsive dermatoses considering the severity, nature, localization of the pathological process, duration of the disease, previous treatment and its effectiveness, and patient’s age enhances the effectiveness of therapy during exacerbations, allows avoiding adverse effects, significantly reduces the systemic pharmacological load, provides stable long-term remission of the disease, and, eventually, significantly improves the quality of life of these patients.